PHC and Cyfuse enhance 3D cell product manufacturing

PHC Corporation and Cyfuse Biomedical K.K., both based in Tokyo, have announced a significant advance in 3D cell product manufacturing. They have developed a new production technology aimed at improving the quality and stability of 3D cell products, essential for regenerative and cell therapies. This breakthrough results from a partnership between the two companies. The new system allows for real-time monitoring of 3D cell products. Historically, keeping track of these living cells in three-dimensional structures has been difficult. With this advancement, researchers can better ensure the stability of these products during manufacturing. Cyfuse used its unique Bio 3D Printing technology to create the 3D cell structures. Meanwhile, PHC applied its in-line monitoring technology to observe the cells’ metabolic activity. This collaboration has led to enhancements in the cultivation of these valuable cell products. Looking ahead, PHC and Cyfuse plan to develop an advanced cell expansion system called a circulation cell culture system. This technology will help optimize the manufacturing process by identifying important parameters and continuously monitoring cell conditions. The companies will share their findings at an upcoming conference in Yokohama, Japan, from March 20 to 22, 2025. They believe their work will contribute to advancements in regenerative medicine and cell therapy. Both PHC and Cyfuse aim to drive innovation in production technologies and expand their impact in the healthcare field. They are committed to improving the manufacturing processes and creating new products that benefit society.